证券代码：300753 证券简称：爱朋医疗 公告编号：2023-033 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 根据《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要 求（2022 年修订）》《深圳证券交易所上市公司自律监管指引第 2 号——创业 板上市公司规范运作（2023 年 8 月修订）》及相关格式指引的规定，江苏爱朋 医疗科技股份有限公司 （以下简称"公司"或"本公司"）董事会对募集资金 2023 年半年度存放与使用情况专项说明如下： 一、募集资金基本情况 (一) 实际募集资金金额和资金到账时间 江苏爱朋医疗科技股份有限公司 募集资金2023年半年度存放与使用情况的专项报告 -1- 经中国证券监督管理委员会证监许可〔2018〕1802 号文核准，并经深圳证 券交易所同意，本公司由主承销商广发证券股份有限公司采用网下向投资者询价 配售和网上按市值向持有深圳市场非限售 A 股或非限售存托凭证市值的社会公 众投资者定价发行相结合的方式，向社会公众公开发行人民币普通股（A 股）股 票 2,020 万股，发行价为每股人民币 15.80 元 ...

证券代码：300753 证券简称：爱朋医疗 公告编号：2023-029 江苏爱朋医疗科技股份有限公司 第三届董事会第五次会议决议公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 一、董事会会议召开情况 江苏爱朋医疗科技股份有限公司（以下简称"公司"）第三届董事会第五次会议 通知及会议材料于2023年8月16日以电话和邮件形式向公司全体董事发出。会议于 2023年8月28日在上海市闵行区联航路1188号3号楼公司会议室以现场结合通讯的方 式召开。本次会议应出席董事7名，实际出席董事7名。会议由董事长王凝宇先生主持， 公司监事、高管列席了本次会议，会议出席人数、召集、召开和表决程序符合《公司 法》等相关法律法规以及《公司章程》的相关规定。 二、董事会会议审议情况 具体内容详见公司同日于巨潮资讯网（www.cninfo.com.cn）披露的《2023年半年度 报告》《2023年半年度报告摘要》。 表决结果：7票同意，0票反对，0票弃权。 2、审议通过《募集资金2023年半年度存放与使用情况的专项报告》 公司募集资金2023年半年度存放与使用情况符合中国证监会、深 ...

证券代码：300753 证券简称：爱朋医疗 公告编号：2023-030 一、 监事会会议召开情况 江苏爱朋医疗科技股份有限公司（以下简称"公司"）第三届监事会第五次会议通 知及会议材料于2023年8月16日以电话和邮件形式向公司全体监事发出，会议于2023年 8月28日在上海市闵行区联航路1188号3号楼公司会议室以现场结合通讯的方式召开。 本次会议应出席监事3人，实际出席监事3人，会议由公司监事会主席袁新闯先生主持， 会议出席人数、召集、召开和表决程序符合《公司法》等相关法律法规以及《公司章 程》的相关规定。 二、监事会会议审议情况 本次会议以记名方式投票表决，逐项审议通过以下议案： 1.审议通过《2023年半年度报告及其摘要》 监事会认为：董事会编制和审核《2023年半年度报告》《2023年半年度报告摘 要》的程序符合法律、行政法规和中国证监会的规定，报告内容真实、准确、完整地反 映了公司的实际情况，没有虚假记载、误导性陈述或者重大遗漏。 江苏爱朋医疗科技股份有限公司 第三届监事会第五次会议决议公告 本公司及监事会全体成员保证信息披露内容真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 表决结果 ...

一、关于公司2023年半年度募集资金存放与使用情况专项报告的独立意见 经核查，我们认为：公司编制的《募集资金2023年半年度存放与使用情况 的专项报告》内容真实、准确、完整，不存在虚假记载、误导性陈述和重大遗 漏。2023年半年度，公司募集资金的管理和使用符合中国证监会、深圳证券交 易所关于上市公司募集资金使用和管理的相关规定，不存在违反募集资金管理 和使用相关规定、损害股东利益的情形。 江苏爱朋医疗科技股份有限公司独立董事 关于第三届董事会第五次会议相关事项的独立意见 根据《上市公司独立董事规则》《深圳证券交易所上市公司自律监管指引 第2号——创业板上市公司规范运作》《江苏爱朋医疗科技股份有限公司章程》 （以下简称"《公司章程》"）《江苏爱朋医疗科技股份有限公司独立董事工 作制度》等相关法律、行政法规、规章制度的有关规定，作为公司的独立董 事，本着严谨、负责的态度，对江苏爱朋医疗科技股份有限公司（以下简称 "公司"）第三届董事会第五次会议审议的相关事项进行监督和审议，基于独 立判断立场，发表如下独立意见： 陶宏迅（签字）： 江苏爱朋医疗科技股份有限公司 2023年8月28日 二、关于控股股东、实际控制人及其 ...

Financial Performance - 2022 annual revenue was 323.8081 million yuan, a decrease of 29.79% year-on-year [7] - Pain management business revenue was 117.3916 million yuan, down 53.46% year-on-year [7] - Nasal care business revenue was 126.1041 million yuan, down 5.82% year-on-year [7] - Net profit attributable to shareholders was -76.3774 million yuan, a decrease of 241.27% year-on-year [7] - Q1 2023 revenue was 94.0682 million yuan, up 29.22% year-on-year [11] - Q1 2023 net profit was 1.2156 million yuan, up 111.06% year-on-year [11] Business Segments Pain Management - Focused on acute, chronic, and intractable pain management [11] - New non-DEHP material infusion devices launched for pregnant women and adolescents [11] - Developed MCB pump + non-DEHP infusion device + iPainfree pain management system [7] - Expanding into non-public hospitals and non-anesthesia departments [11] Nasal and Upper Airway Management - Nasal care products revenue accounted for 38.94% of total revenue in 2022 [10] - Retail business revenue reached 107.1526 million yuan, up 14.26% year-on-year [10] - Expanded indications for Noseclean nasal spray to include acute upper respiratory infections [10] - Increased online investment in nasal care products [7] CXO Business - Established medical device CXO project incubation centers in 2020 [8] - Provides capital, R&D, registration, production, and marketing support [8] - Set up a 50 million yuan private equity fund for project incubation [8] R&D and Innovation - 2022 R&D investment was 34.9463 million yuan, accounting for 10.79% of revenue [9] - 16 R&D projects across 9 major categories in pain and nasal management [9] - Key projects include pain assessment algorithms, anesthesia depth monitors, and nasal irrigation materials [9] - Launched new products including Noseclean nasal spray and non-DEHP infusion devices [9] Market Trends and Opportunities - Domestic anesthesia depth monitors gaining market share due to government procurement policies [8] - Epidural analgesia included in medical insurance in over 10 provinces [11] - Nasal irrigation market potential supported by COVID-19 expert consensus [12] - Allergic rhinitis prevalence in China is 17.6% [12] Strategic Initiatives - Building a smart product and service ecosystem focused on single disease management [5] - Expanding into perioperative rapid recovery and medical aesthetic safety [7] - Strengthening market access and hospital entry for new products [7] - Enhancing brand exposure and customer loyalty for nasal care products [7]

证券代码：300753 证券简称：爱朋医疗 公告编号：2023-020 江苏爱朋医疗科技股份有限公司 关于举行2022年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 江苏爱朋医疗科技股份有限公司（以下简称"公司"）已于2023年4月24日在 巨潮资讯网（http://www.cninfo.com.cn）上披露了《2022年年度报告》全文及其摘 要。 特此公告。 江苏爱朋医疗科技股份有限公司董事会 2023 年5月8日 为了便于投资者更全面地了解公司2022年度经营情况，公司定于2023年5月16 日（星期二）15:00-17:00 举行2022年度网上业绩说明会，本次年度业绩说明会将通 过深圳证券交易所提供的"互动易"平台举行，投资者可登陆"互动易" 网站 （http://irm.cninfo.com.cn），进入"云访谈"栏目参与本次业绩说明会。 出席本次业绩说明会的人员有：公司董事长王凝宇先生、副总经理兼财务总监 袁栋麒先生、副总经理兼董事会秘书缪飞先生、独立董事侯利阳先生。 为充分尊重投资者，提升公司与投资者的交流效率和针对性， ...

江苏爱朋医疗科技股份有限公司2022年年度报告全文 江苏爱朋医疗科技股份有限公司 2022 年年度报告 ...

Financial Performance - The company's revenue for Q1 2023 was ¥94,068,177.53, representing a 29.22% increase compared to ¥72,794,357.61 in the same period last year[5] - Net profit attributable to shareholders was ¥1,215,574.66, a significant turnaround from a loss of ¥10,987,817.03 in the previous year, marking an increase of 111.06%[5] - The net profit after deducting non-recurring gains and losses was ¥975,082.81, compared to a loss of ¥10,948,474.02 last year, reflecting an increase of 108.91%[5] - Operating profit for Q1 2023 was CNY 2,768,976.71, a significant recovery from a loss of CNY 12,312,975.32 in the same period last year[19] - Net profit for Q1 2023 was CNY 1,250,235.16, compared to a net loss of CNY 11,460,471.11 in Q1 2022, marking a turnaround in profitability[19] - The company reported a basic and diluted earnings per share of CNY 0.0096, recovering from a loss of CNY 0.0872 per share in the previous year[19] Cash Flow - Cash flow from operating activities showed a net outflow of ¥60,865,461.63, slightly worsening from a net outflow of ¥58,957,573.53 in the same period last year, a change of -3.24%[5] - Cash generated from operating activities was CNY 80,064,517.56, up from CNY 74,541,426.93 in Q1 2022, indicating improved cash flow[21] - The net cash flow from operating activities for Q1 2023 was -60,865,461.63 CNY, compared to -58,957,573.53 CNY in Q1 2022, indicating a slight increase in cash outflow[22] - Total cash inflow from operating activities was 87,834,681.51 CNY, while cash outflow totaled 148,700,143.14 CNY, resulting in a net cash flow deficit[22] - Cash flow from investing activities showed a net outflow of -142,921,162.72 CNY, significantly higher than -62,097,328.20 CNY in the same period last year[22] - Cash flow from financing activities resulted in a net outflow of -1,463,619.19 CNY, contrasting with a net inflow of 9,563,006.67 CNY in Q1 2022[22] - The ending balance of cash and cash equivalents was 43,501,364.85 CNY, down from 162,770,955.50 CNY at the end of Q1 2022[22] Assets and Liabilities - The company's total assets decreased by 5.07% to ¥826,125,197.49 from ¥870,213,234.55 at the end of the previous year[5] - Total liabilities decreased to CNY 138,512,800.30 from CNY 183,851,072.51, indicating a reduction in financial obligations[17] - The company’s equity attributable to shareholders increased to CNY 686,795,935.87 from CNY 685,580,361.21, showing slight growth in shareholder value[17] - The total current assets decreased from CNY 445,382,651.89 at the beginning of the year to CNY 400,705,725.07 by the end of the quarter, representing a decline of approximately 10%[15] - The total non-current assets slightly decreased from CNY 261,860,629.26 to CNY 261,498,926.17, a marginal decline of around 0.14%[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 9,800[9] - The company reported a reduction in restricted shares from 51,567,575 to 45,053,063, a decrease of approximately 13%[11] - Shareholder Zhang Zhihui reduced his holdings by 252,000 shares, accounting for 1.9992% of the total share capital[13] - Shareholder Guan Jifeng reported a reduction of 190,962 shares, representing 0.16% of the total share capital[13] Investments and R&D - The company’s investment activities resulted in a cash outflow of ¥142,921,162.72, which is a 130.16% increase compared to ¥62,097,328.20 in the same period last year[8] - The company has ongoing investments in long-term equity, with a slight decrease from CNY 50,125,753.65 to CNY 49,917,203.04[15] - Research and development expenses for Q1 2023 were CNY 9,687,121.04, slightly down from CNY 10,224,739.54 in Q1 2022, indicating a focus on cost management[18] Other Information - The company reported a significant increase in accounts receivable notes by 655.51%, reaching ¥11,895,464.09, primarily due to settlements from certain customers[8] - Cash and cash equivalents decreased significantly from CNY 249,251,608.39 to CNY 43,501,364.85, a drop of about 83%[15] - Accounts receivable increased from CNY 110,834,769.72 to CNY 122,070,035.20, indicating a growth of approximately 10%[15] - Inventory rose from CNY 61,039,583.17 to CNY 68,062,416.37, reflecting an increase of about 11%[15] - The company is focusing on expanding its market presence and developing new technologies, although specific figures were not disclosed in the report[13] - The first quarter report was not audited[23]

Group 1: Product Demand and Market Trends - The nasal irrigation for COVID-19 prevention has been recognized by experts, with significant demand expected post-pandemic [1] - Sales of nasal spray products surged after the relaxation of COVID-19 restrictions in Hong Kong, although complete comparative data is not yet available [2] - The company has sold over 30 million bottles of nasal care products, indicating a leading market share [3] Group 2: Financial Performance and Challenges - Revenue growth for nasal care products in the first three quarters of the year has slowed due to the impact of COVID-19 restrictions in Shanghai [2] - The company’s anesthetic depth monitoring device generated sales of over 4 million yuan in 2021, primarily targeting tertiary hospitals [3] - The chronic pain management market has a significant potential, with approximately 170 million pain patients in China [4] Group 3: Competitive Landscape and Strategies - The nasal care product market is competitive, with the company focusing on clinical research and brand promotion [2] - The company plans to expand its anesthetic depth monitoring device market share, currently dominated by imported brands [3] - The postoperative analgesia market is projected to grow, with the company holding a market share of about 16% in this segment [5] Group 4: Future Outlook - The market for postoperative analgesia is expected to grow by approximately 10% annually, driven by increased surgical volumes and improved analgesia rates [5] - The electronic drug delivery pump market is estimated to be around 1.5 billion yuan, with future growth expected to reach 3 billion yuan [5]